2.15
-0.03 (-1.38%)
| Penutupan Terdahulu | 2.18 |
| Buka | 2.18 |
| Jumlah Dagangan | 1,459,432 |
| Purata Dagangan (3B) | 1,954,321 |
| Modal Pasaran | 800,356,928 |
| Harga / Jualan (P/S) | 2.90 |
| Harga / Buku (P/B) | 1.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2024 |
| Margin Keuntungan | -87.05% |
| Margin Operasi (TTM) | -29.42% |
| EPS Cair (TTM) | -0.880 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -14.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 118.03% |
| Nisbah Semasa (MRQ) | 3.88 |
| Aliran Tunai Operasi (OCF TTM) | -127.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.07 M |
| Pulangan Atas Aset (ROA TTM) | -13.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Standard BioTools Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -1.0 |
| Purata | -1.30 |
|
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.95% |
| % Dimiliki oleh Institusi | 72.14% |
| Julat 52 Minggu | ||
| Median | 2.50 (16.28%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| TD Cowen | 31 Oct 2024 | 2.50 (16.28%) | Beli | 1.96 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| EGHOLM MICHAEL | - | 1.61 | -28,795 | -46,360 |
| Jumlah Keseluruhan Kuantiti Bersih | -28,795 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -46,360 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 1.61 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| EGHOLM MICHAEL | Pegawai | 20 Nov 2024 | Dibuang (-) | 28,795 | 1.61 | 46,360 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Nov 2024 | Pengumuman | Standard BioTools Appoints Alex Kim as Chief Financial Officer |
| 31 Oct 2024 | Pengumuman | Standard BioTools to Participate in Upcoming Investor Conferences |
| 30 Oct 2024 | Pengumuman | Standard BioTools Reports Third Quarter 2024 Financial Results |
| 16 Oct 2024 | Pengumuman | Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 |
| 24 Sep 2024 | Pengumuman | Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform |
| 18 Sep 2024 | Pengumuman | Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |